CLN 978
Alternative Names: CD19xCD3; CLN-978; NexGemLatest Information Update: 20 Aug 2025
At a glance
- Originator Cullinan Therapeutics
- Class Antineoplastics; Antirheumatics; Bispecific antibodies; Immunoglobulin Fc fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Rheumatoid arthritis; Sjogren's syndrome; Systemic lupus erythematosus
- Discontinued Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 07 Aug 2025 Phase-I clinical trials in Sjogren's syndrome in Europe (SC) before August 2025
- 07 Aug 2025 Cullinan Therapeutics receives regulatory approval for Phase-I clinical trials in Sjogren's syndrome in Europe before August 2025
- 27 Jun 2025 Phase-I clinical trials in Sjogren's syndrome in USA (SC) (NCT07041099)